A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium

Trial Profile

A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Vinflunine
  • Indications Bladder cancer; Renal cancer; Urethral cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Results of phase II part of the study (n=70) published in the Annals of Oncology
    • 18 Feb 2017 Primary endpoint of overall response rate has not been met, according to results presented at the 2017 Genitourinary Cancers Symposium..
    • 18 Feb 2017 Results of phase II part of this study (n=70) presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top